Lantheus Holdings, Inc. (LNTH) stock
LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3010% above fair value
$101.59+0.34 (+0.34%)
Close on Nov 13, 2026Market cap $6.63BP/E 25.1Yield –
Lantheus r&d expenses
Research and development expenses are spending on new products and technology.
Lantheus's R&D Expenses for the twelve months ending Sep 30, 2026 was $217.83M, up 31.9% year over year. For fiscal 2025 it was $177.31M, up 5.5% from the year before. Over ten years it grew 28.6% a year on average. The highest annual figure on record is $311.68M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.31M | +5.5% |
| FY2024 | Dec 31, 2024 | $168.10M | +116.3% |
| FY2023 | Dec 31, 2023 | $77.71M | -75.1% |
| FY2022 | Dec 31, 2022 | $311.68M | +593.1% |
| FY2021 | Dec 31, 2021 | $44.97M | +37.1% |
| FY2020 | Dec 31, 2020 | $32.79M | +63.8% |
| FY2019 | Dec 31, 2019 | $20.02M | +17.3% |
| FY2018 | Dec 31, 2018 | $17.07M | -5.8% |
| FY2017 | Dec 31, 2017 | $18.13M | +48.5% |
| FY2016 | Dec 31, 2016 | $12.20M | -15.0% |
| FY2015 | Dec 31, 2015 | $14.36M | +5.0% |
| FY2014 | Dec 31, 2014 | $13.67M | -55.1% |
| FY2013 | Dec 31, 2013 | $30.46M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $92.76M | +93.2% |
| Q2 FY2026 | Jun 30, 2026 | $38.20M | -16.0% |
| Q1 FY2026 | Mar 31, 2026 | $39.38M | +8.4% |
| Q4 FY2025 | Dec 31, 2025 | $47.48M | +34.4% |
| Q3 FY2025 | Sep 30, 2025 | $48.03M | +98.9% |
| Q2 FY2025 | Jun 30, 2025 | $45.49M | -24.9% |
| Q1 FY2025 | Mar 31, 2025 | $36.31M | -24.4% |
| Q4 FY2024 | Dec 31, 2024 | $35.33M | +110.0% |
| Q3 FY2024 | Sep 30, 2024 | $24.15M | +67.1% |
| Q2 FY2024 | Jun 30, 2024 | $60.60M | +281.1% |
| Q1 FY2024 | Mar 31, 2024 | $48.02M | +57.3% |
| Q4 FY2023 | Dec 31, 2023 | $16.82M | -93.8% |
| Q3 FY2023 | Sep 30, 2023 | $14.45M | +15.4% |
| Q2 FY2023 | Jun 30, 2023 | $15.90M | +7.9% |
| Q1 FY2023 | Mar 31, 2023 | $30.53M | +150.2% |
| Q4 FY2022 | Dec 31, 2022 | $272.23M | +2310.6% |
| Q3 FY2022 | Sep 30, 2022 | $12.52M | +11.2% |
| Q2 FY2022 | Jun 30, 2022 | $14.74M | +22.2% |
| Q1 FY2022 | Mar 31, 2022 | $12.20M | +17.8% |
| Q4 FY2021 | Dec 31, 2021 | $11.29M | -10.6% |
| Q3 FY2021 | Sep 30, 2021 | $11.25M | -3.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.06M | +173.0% |
| Q1 FY2021 | Mar 31, 2021 | $10.36M | +155.9% |
| Q4 FY2020 | Dec 31, 2020 | $12.64M | +185.0% |
| Q3 FY2020 | Sep 30, 2020 | $11.68M | +140.4% |
| Q2 FY2020 | Jun 30, 2020 | $4.42M | -23.8% |
| Q1 FY2020 | Mar 31, 2020 | $4.05M | -17.9% |
| Q4 FY2019 | Dec 31, 2019 | $4.43M | -2.6% |
| Q3 FY2019 | Sep 30, 2019 | $4.86M | +12.6% |
| Q2 FY2019 | Jun 30, 2019 | $5.80M | +37.5% |
| Q1 FY2019 | Mar 31, 2019 | $4.93M | +23.6% |
| Q4 FY2018 | Dec 31, 2018 | $4.55M | +14.5% |
| Q3 FY2018 | Sep 30, 2018 | $4.32M | +21.4% |
| Q2 FY2018 | Jun 30, 2018 | $4.22M | -19.6% |
| Q1 FY2018 | Mar 31, 2018 | $3.99M | -25.5% |
| Q4 FY2017 | Dec 31, 2017 | $3.98M | +7.2% |
| Q3 FY2017 | Sep 30, 2017 | $3.55M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.24M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.35M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.71M | – |
See a number that looks wrong?